113-N16B
Based on 1 Customer Validation
113-N16B is an ionizable cationic lipid that can be used for the synthesis of lipid nanoparticles. 113-N16B delivers mRNA to pulmonary endothelial cells. 113-N16B can be formulated as a component into hybrid lipid nanoparticles for lung-specific delivery of mRNA (including MFSD7C mRNA and luciferase mRNA) in mice. 113-N16B is applicable to research related to lymphangioleiomyomatosis, sickle cell disease, and hemolysis-induced lung injury.
For research use only. We do not sell to patients.
- Purity : 98.0%
- Formula: C73H147N7O4S8
- Molecular Weight:1443.51
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
113-N16B (LNP formulation; 0.5 mg/kg mRNA; intravenous injection; single administration) specifically delivers fLuc mRNA to the lungs of healthy Balb/c mice[1].
113-N16B formulated lipid nanoparticles (0.5 mg/kg; i.v.) enable lung-specific mRNA delivery, while 113-N16B lipid nanoparticles loaded with MFSD7C mRNA (0.5 mg/kg; i.v.; once weekly for 4 weeks) upregulate MFSD7C expression in mouse lung tissues[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ai14 Cre reporter mice (transgenic)[1]
-
Dosage:0.75 mg mRNA equiv./kg
-
Administration:i.v.; single dose
-
Result:Achieved tdTomato expression specifically localized to the lungs.
Transfected 69.6% of pulmonary endothelial cells, 7.3% of pulmonary epithelial cells, and 18.9% of pulmonary macrophages.
-
Animal Model:Balb/c mice (female, 6 to 8 weeks old)[1]
-
Dosage:0.5 mg/kg mRNA
-
Administration:i.v.; single dose
-
Result:Detected bioluminescence signals (luciferase expression) primarily in the lungs, confirming lung-targeted mRNA delivery.
-
Animal Model:HbSS-Townes, HbAA-Townes, 7Cflox/flox, 7C-/- (12-month-old HbSS-Townes/HbAA-Townes; 8-week-old 7Cflox/flox/7C-/-; PHZ-challenged 7C-/- for hemolytic lung injury model)[2]
-
Dosage:0.5 mg/kg (luciferase mRNA-loaded LNPs; single dose); 0.5 mg/kg MFSD7C mRNA per dose (MFSD7C mRNA-loaded LNPs; weekly for 4 weeks)
-
Administration:i.v. (single dose for luciferase mRNA-loaded LNPs); i.v.; weekly; 4 weeks (MFSD7C mRNA-loaded LNPs)
-
Result:Confirmed lung-specific delivery of mRNA via increased bioluminescence intensity in the lungs of mice given luciferase mRNA-loaded 113-N16B lipid nanoparticles.
Elevated MFSD7C protein expression in mouse lung tissue following administration of MFSD7C mRNA-loaded 113-N16B lipid nanoparticles.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 1443.51
-
Formula C73H147N7O4S8
-
Color Colorless to light yellow
-
SMILES
O=C(CCN(CCC(NCCSSCCCCCCCCCCCC)=O)CCN(C)CCN(CCC(NCCSSCCCCCCCCCCCC)=O)CCC(NCCSSCCCCCCCCCCCC)=O)NCCSSCCCCCCCCCCCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 10 mg/mL (6.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Qiu M, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proceedings of the National Academy of Sciences of the United States of America. 2022 Feb 22;119(8):e2116271119. [Content Brief]
[2]. Wang H, et al. MFSD7C protects hemolysis-induced lung impairments by inhibiting ferroptosis. Nature communications. 2024 Sep 19;15(1):8226. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6928 mL | 3.4638 mL | 6.9276 mL | 17.3189 mL |
| 5 mM | 0.1386 mL | 0.6928 mL | 1.3855 mL | 3.4638 mL |
113-N16B Related Classifications
HY-153737 Related Classifications
Powered by Bioz